Rilpivirine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rilpivirine" in English language version.

refsWebsite

Global rank English rank

7europa.eu

68^th place

117^th place

6nih.gov

4^th place

6fda.gov

447^th place

338^th place

3web.archive.org

1^st place

3doi.org

2^nd place

2semanticscholar.org

11^th place

8^th place

2clinicaltrials.gov

5,225^th place

4,062^nd place

1medicines.org.uk

3,823^rd place

2,387^th place

1tibotec.com

low place

1retroconference.org

low place

1drugs.com

399^th place

333^rd place

1aidsmap.com

low place

aidsmap.com

"Eviplera". Aidsmap. March 2011. Retrieved September 1, 2014.

clinicaltrials.gov

"A Clinical Trial in Treatment naïve HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine". ClinicalTrials.gov. National Institutes of Health. October 25, 2012. Retrieved January 1, 2014.
"A Clinical Trial in Treatment naïve HIV-Subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors". ClinicalTrials.gov. National Institutes of Health. May 14, 2012. Retrieved January 1, 2014.

doi.org

Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, et al. (August 2006). "Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects". AIDS. 20 (13): 1721–1726. doi:10.1097/01.aids.0000242818.65215.bd. PMID 16931936. S2CID 26078073.
Lade JM, Avery LB, Bumpus NN (October 2013). "Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison". Antimicrobial Agents and Chemotherapy. 57 (10): 5067–5079. doi:10.1128/AAC.01401-13. PMC 3811466. PMID 23917319.
Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. (July 2011). "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial". Lancet. 378 (9787): 238–246. doi:10.1016/S0140-6736(11)60936-7. PMID 21763936. S2CID 7313885.

drugs.com

Rilpivirine Monograph. Accessed 2021-02-23.

europa.eu

ema.europa.eu

"Edurant EPAR". European Medicines Agency (EMA). 12 December 2011. Retrieved 4 January 2021.
"Rekambys EPAR". European Medicines Agency (EMA). 13 October 2020. Retrieved 4 January 2021.
"First long-acting injectable antiretroviral therapy for HIV recommended approval". European Medicines Agency (EMA) (Press release). 16 October 2020. Retrieved 16 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Rekambys: EPAR – public assessment report" (PDF). European Medicines Agency. 2021-02-22.
"Vocabria: EPAR – Product information" (PDF). European Medicines Agency. 2021-01-05.
"Edurant: EPAR – public assessment report" (PDF). European Medicines Agency. 2021-01-04.
"Rekambys: Pending EC decision". European Medicines Agency (EMA). 16 October 2020. Retrieved 16 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov

"Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". U.S. Food and Drug Administration (FDA). August 10, 2011.
"FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV". U.S. Food and Drug Administration (FDA) (Press release). 21 January 2021. Retrieved 21 January 2021. This article incorporates text from this source, which is in the public domain.
"Cabenuva and Vocabria approved for HIV infection". U.S. Food and Drug Administration (FDA). 27 January 2021. Retrieved 27 January 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves new HIV treatment" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 2017-01-18. Retrieved 2011-05-20.

accessdata.fda.gov

"Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide) Tablets". U.S. Food and Drug Administration (FDA). 29 November 2016. Retrieved 23 January 2021.
"Drug Approval Package: Edurant (rilpivirine) NDA #202022#". U.S. Food and Drug Administration (FDA). 20 August 2013. Retrieved 23 January 2021.

medicines.org.uk

"Edurant 25 mg tablets - Summary of Product Characteristics (SmPC)". (emc). 21 January 2020. Retrieved 4 January 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Stellbrink HJ (October 2007). "Antiviral drugs in the treatment of AIDS: what is in the pipeline ?". European Journal of Medical Research. 12 (9): 483–495. PMID 17933730.
Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, et al. (August 2006). "Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects". AIDS. 20 (13): 1721–1726. doi:10.1097/01.aids.0000242818.65215.bd. PMID 16931936. S2CID 26078073.
Lade JM, Avery LB, Bumpus NN (October 2013). "Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison". Antimicrobial Agents and Chemotherapy. 57 (10): 5067–5079. doi:10.1128/AAC.01401-13. PMC 3811466. PMID 23917319.
Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. (July 2011). "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial". Lancet. 378 (9787): 238–246. doi:10.1016/S0140-6736(11)60936-7. PMID 21763936. S2CID 7313885.

dailymed.nlm.nih.gov

"Edurant- rilpivirine hydrochloride tablet, film coated". DailyMed. Retrieved 4 January 2021.

ncbi.nlm.nih.gov

Lade JM, Avery LB, Bumpus NN (October 2013). "Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison". Antimicrobial Agents and Chemotherapy. 57 (10): 5067–5079. doi:10.1128/AAC.01401-13. PMC 3811466. PMID 23917319.

retroconference.org

Pozniak A, Morales-Ramirez J, Mohap L, et al. "48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. Oral abstract 144LB". 14th Conference on Retroviruses and Opportunistic Infections. Archived from the original on October 19, 2007.

semanticscholar.org

api.semanticscholar.org

Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, et al. (August 2006). "Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects". AIDS. 20 (13): 1721–1726. doi:10.1097/01.aids.0000242818.65215.bd. PMID 16931936. S2CID 26078073.
Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. (July 2011). "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial". Lancet. 378 (9787): 238–246. doi:10.1016/S0140-6736(11)60936-7. PMID 21763936. S2CID 7313885.

tibotec.com

"TMC278 — A new NNRTI". Tibotec. Archived from the original on 2008-12-20. Retrieved 2010-03-07.

web.archive.org

"TMC278 — A new NNRTI". Tibotec. Archived from the original on 2008-12-20. Retrieved 2010-03-07.
Pozniak A, Morales-Ramirez J, Mohap L, et al. "48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. Oral abstract 144LB". 14th Conference on Retroviruses and Opportunistic Infections. Archived from the original on October 19, 2007.
"FDA approves new HIV treatment" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 2017-01-18. Retrieved 2011-05-20.